Title
Deferoxamine inhibits methyl mercury-induced increases in reactive oxygen species formation in rat brain

Permalink
https://escholarship.org/uc/item/9hk6m0mh

Journal
Toxicology and Applied Pharmacology, 112(1)

ISSN
0041-008X

Authors
LeBel, Carl P
Ali, Syed F
Bondy, Stephen C

Publication Date
1992

DOI
10.1016/0041-008X(92)90292-z

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Deferoxamine Inhibits Methyl Mercury-Induced Increases in Reactive Oxygen Species Formation in Rat Brain

Deferoxamine Inhibits Methyl Mercury-Induced Increases in Reactive Oxygen Species Formation in Rat Brain. LeBel, C. P., Ali, S. F., and Bondy, S. C. (1992). Toxicol. Appl. Pharmacol. 112, 161-165.

It has been suggested that methyl mercury may express its neurotoxicity by way of iron-mediated oxidative damage. Therefore, the effect of deferoxamine, a potent iron-chelator, on methyl mercury-induced increases in reactive oxygen species formation was studied in rat brain. The generation rate of reactive oxygen species was estimated in crude synaptosomal fractions using the probes 2',7'-dichlorofluorescin diacetate and dihydrorhodamine 123. The formation rate of the fluorescent oxidation products was used as the measure of reactive oxygen species generation. Seven days after a single injection of methyl mercury (5 mg/kg, ip), the formation rate of reactive oxygen species was significantly increased in the cerebellum. Pretreatment with deferoxamine (500 mg/kg, ip) completely prevented the methyl mercury-induced increase in cerebellar reactive oxygen species generation rates. The oxidative consequences of in vitro exposure to methyl mercury (20 µM) were also inhibited by deferoxamine (100 µM). The formation of the iron-saturated complex ferrioxamine was not affected by a 10-fold excess of methylmercuric chloride or mercuric chloride, suggesting that a deferoxamine-mercurial complex does not form. The findings in this study: (1) provide evidence that iron-catalyzed oxygen radical-producing reactions play a role in methyl mercury neurotoxicity, (2) demonstrate the potential of fluorescent probes as a measure of reactive oxygen species formation, and (3) provide support for iron-chelator therapy in protection against xenobiotic-induced oxidative damage. © 1992 Academic Press, Inc.

Reactive oxygen species such as superoxide anion, hydrogen peroxide, ferryl ion, and hydroxyl radical, if present in excess, are thought to be initiators of peroxidative cell damage (Freeman and Crapo, 1982; Halliwell and Gutteridge, 1984, 1986). The nervous system is exquisitely sensitive to peroxidative damage since it is rich in oxidizable substrates such as lipids and catecholamines (Halliwell and Gutteridge, 1985). With this in mind, there is increasing evidence to suggest that oxidative damage-inducing free radicals may play a role in the underlying biochemical mechanisms involved in the neurotoxicity of methylmercuric chloride (MeHg; Ganther, 1978, 1980). Studies have reported that MeHg stimulates lipid peroxidation (Yonaha et al., 1983) and the lipoperoxidative effects of MeHg are mitigated by the antioxidant α-tocopherol (vitamin E; Halliwell and Gutteridge, 1985; Kasuya, 1975; Bondy and McKee, 1990). Additionally, this laboratory has recently demonstrated that both in vivo and in vitro exposures to MeHg increased the formation rate of reactive oxygen species in mouse brain (LeBel et al., 1990), effects that were observed only in the cerebellum, the brain region believed to be selectively vulnerable to MeHg (Syverson et al., 1981). The latter findings were demonstrated with the aid of the probe 2',7'-dichlorofluorescin diacetate (DCFH-DA), a stable nonfluorescent molecule that readily crosses cell membranes and is hydrolyzed by intracellular esterases to nonfluorescent 2',7'-dichlorofluorescein (DCF). Several reactive oxygen species appear to be responsible for the oxidation of DCFH (LeBel et al., 1991).

It has become increasingly apparent that transition metals such as iron and copper play critical roles in toxicological and pathological phenomena that lead to oxidative cell damage (for review see Aust et al., 1985). To prevent such phenomena, various chelating agents have been employed to minimize the participation of transition metals. One such agent is the iron chelator deferoxamine which has a high affinity for ferric iron (Keberle, 1964) and has been used clinically in cases of iron overload (Summers et al., 1979; Mahoney et al., 1989).

Of toxicological significance is the fact that deferoxamine has been used to protect against the effects of lindane (Videla et al., 1989), paraquat (Kohen and Chevion, 1985), diquat (Smith, 1987), ethanol (Abu-Murad and Nordmann, 1983; Nordmann et al., 1987), acetaminophen, and carbon tetrahloride (Younes and Siegers, 1985). The protection afforded by deferoxamine has been estimated using a variety of methodologies. Its ability to inhibit lipid peroxidation has been assayed with the thiobarbituric acid colorimetric procedure (Smith, 1987; Younes and Siegers, 1985).

The advantage of utilizing DCFH-DA is that it provides a direct measure of the formation rate of reactive oxygen species and, therefore, conclusions regarding the role of these species are not based on secondary mechanisms such as lipid peroxidation. The aim of the present study was to employ deferoxamine to investigate the role of iron-catalyzed oxygen formation.

1 This work was supported by NIH Grants ES 04071 and ES 07157.
radical reactions in rat brain, measured using fluorescent probes, following in vivo and in vitro exposure to MeHg.

MATERIALS AND METHODS

**Materials.** DCFH-DA, dihydrodorhamidine 123 (DHR 123), and rhodamine 123 (R123) were obtained from Molecular Probes, Inc. (Eugene, OR), and DCF was purchased from Polysciences, Inc. (Warrington, PA). Deferoxamine mesylate was obtained from Sigma Chemical Co. (St. Louis, MO), and MeHg from ICN Pharmaceutical, K&K Labs (Plainview, NY).

**Animals and treatment.** Male CR 1 CD rats (National Center for Toxicological Research Breeding Colony, Jefferson, AR) weighing 215-235 g were employed in this study. Rats were housed two per cage with woodchip bedding and maintained on a 12-h light/dark cycle in a temperature-controlled (20 ± 1°C) room. Food (Purina Laboratory Chow, St. Louis, MO) and tap water were provided ad libitum. MeHg was dissolved in deionized-distilled water and administered in a single dose of 5.0 mg/kg intraperitoneally in a volume of 2 ml/kg. Deferoxamine was dissolved in deionized-distilled water and administered in a single intraperitoneal dose of 500 mg/kg (2 ml/kg dose volume) 1 hr before the administration of MeHg. All animals were euthanized seven days after treatment.

**Preparation of P2 fractions.** Rats were euthanized, the brains excised quickly on ice, and the cerebellum, cortex, and brainstem were dissected out. Each region was placed into a microcentrifuge tube, placed at −20°C for 24 hr, and stored at −70°C until crude synaptosomal (P2) preparation. Each region was weighed and homogenized in 10 vol of 0.32 M sucrose. The crude nuclear fraction was removed by centrifugation at 1800g for 10 min at 2°C (tₐ = 11.0 cm). The resulting supernatant fraction was centrifuged at 31,500g for 10 min (tₐ = 11.0 cm) to yield the P2 pellet. The P2 pellet was suspended in Hepes buffer to a concentration of 0.0185 g eq/ml. The composition of Hepes buffer was (mm): NaCl, 120; KCl, 2.5; NaH₂PO₄, 1.2; MgCl₂, 0.1; NaHCO₃, 5.0; glucose, 1.0; CaCl₂, 1.0 and; Hepes, 10.

**Assay for reactive oxygen species.** Quantification of the formation rate of oxygen reactive species was determined as previously described (LeBel et al., 1990). Briefly, P2 fractions were diluted 1:10 with 40 mM Tris (pH 7.4) and loaded with 5 µM DCFH-DA or 10 µM DHR 123 (in methanol) for 15 min at 37°C. Following loading, the fluorescence was recorded prior to (initial) and after an additional 60 min (final) incubation. In studies that investigated the in vitro effects of MeHg (20 µM) and deferoxamine (10-100 µM), the agents were added to P2 fractions (isolated from rat cerebellum) after the initial fluorescence reading. Samples were then incubated for 60 min, followed by recording of the final fluorescence value. The formation of the fluorescent-oxidized derivatives of DCFH and DHR 123, namely DCF and R123, were monitored as follows: DCF, excitation wavelength, 488 nm (bandpass 5 nm), and emission wavelength, 525 nm (bandpass 20 nm); R123, excitation wavelength, 505 nm (bandpass 5 nm) and emission wavelength, 536 nm (bandpass 20 nm). The cuvette holder was thermostatically maintained at 37°C. Autofluorescence of P2 fractions was always less than 6%, and any methanol vehicle effect was recorded and subtracted before calculation of the formation of DCF and R123. DCF and R123 formation were quantified from separate standard curves in methanol (0.05-1.0 µM).

**Assay for ferroxamine formation.** The chelation of deferoxamine and FeSO₄ was determined by the formation of ferroxamine, adapted from the method of Hallaway et al. (1989). In a total volume of 2 ml, a 5-fold excess of FeSO₄ (final concentration 625 µM) was added to a solution of deferoxamine (final concentration 125 µM) in deionized-distilled water. To determine whether deferoxamine was able to chelate MeHg or Hg⁺, a 10-fold excess of either MeHg or HgCl₂ (final concentration 1.25 mM) was also employed. Each solution was allowed to incubate at room temperature (22°C) for 60 min, and the ferroxamine complex formed was measured spectrophotometrically at 429 nm.

**RESULTS AND DISCUSSION**

The generation rates of cerebellar reactive oxygen species following in vivo exposure to MeHg and deferoxamine are presented in Fig. 1. Seven days after a single injection of MeHg (5 mg/kg) the formation rate of reactive oxygen species in P2 fractions isolated from rat cerebellum, as measured by DCF formation, was significantly increased (Fig. 1A). This finding is in agreement with our previous finding that MeHg stimulated the formation rate of reactive oxygen species in mouse cerebellum (LeBel et al., 1990). The data also confirm reports that in both species of rodent, the cerebellum is the brain region that is selectively vulnerable to MeHg-induced morphological damage following in vivo exposure (Syzwerson et al., 1981).

We have previously demonstrated that the chelating agent deferoxamine prevents oxidation of DCFH induced by a

![FIG. 1. The formation rate of cerebellar reactive oxygen species measured by DCF (A) or R123 (B) formation in P2 fractions isolated from animals 7 days after a single exposure to MeHg (5 mg/kg, ip). Values are the mean ± SE, derived from six or seven animals/group. In some groups, deferoxamine (DFO, 500 mg/kg, ip) was given 1 hr prior to MeHg injection. *Significant difference from control value.]
dependent experiments and are expressed as the mean difference from corresponding control value. were isolated from untreated animals. Data were obtained from three independent experiments and are expressed as the mean ± SE. *Significant difference from corresponding control value.

The in vitro effects of MeHg and deferoxamine on the generation rates of reactive oxygen species were also studied. MeHg (20 μM) significantly increased reactive oxygen species formation in cerebellar P2 fraction isolated from control rats (Fig. 2). Addition of deferoxamine in vitro (100 μM) inhibited MeHg-induced increases in cerebellar reactive oxygen species formation, as was the case following in vivo exposure to MeHg, while 10 μM deferoxamine attenuated MeHg's effect. Higher concentrations of deferoxamine (1 mM) completely blocked MeHg stimulation of reactive oxygen species generation; however, control formation rates were also inhibited (data not shown).

Despite the fact that deferoxamine is known to be selective for iron, a possible mechanism by which deferoxamine inhibited MeHg-induced increases in reactive oxygen species generation may have been via chelation of the Hg moiety of MeHg. Therefore, the potential of deferoxamine to chelate MeHg or Hg2+ was investigated by looking at the formation of the iron-saturated deferoxamine complex, ferrioxamine. Even in the presence of a 10-fold excess of either MeHg or HgCl₂, the formation of ferrioxamine was not inhibited (Table 1). No complex-generating absorbance was noted with deferoxamine and MeHg or HgCl₂ in the absence of iron. Although the experiments performed are not unequivocal regarding the ability of deferoxamine to bind mercury, it is unlikely that there are significant amounts of inorganic mercury salts present 1 hr after the administration of MeHg (Racz and Vandewater, 1982). Treatment with deferoxamine alone did not affect the basal rate of formation of reactive oxygen species in rat cerebellum (Fig. 1). In fact, animals pretreated with deferoxamine and subsequently exposed to MeHg appeared to be in better general health (healthier coats, less perinasal staining and chromodacryorrhea) than the group receiving no such treatment before MeHg injection. While deferoxamine has shown some acute toxicity in clinical studies (Whitten et al., 1965, 1966; Westlin, 1966), its therapeutic potential demonstrated in the present study and against other xenobiotic-induced toxicities appears promising.

Since the formation of DCF from DCFH-DA requires the action of intracellular esterases, an alternative probe was used to determined whether MeHg treatment affected intracellular esterase activity. The probe DHR 123 is oxidized by reactive oxygen species to its fluorescent product Rl23, a process that does not require esterases. In vivo exposure to MeHg significantly increased reactive oxygen species formation, as measured by R123 fluorescence, in rat cerebellum, which was also blocked by pretreatment with deferoxamine (Fig. 1B). Again, treatment with deferoxamine alone was without effect. Therefore, the increased rate of formation of DCF following exposure to MeHg did not appear to be related to an effect on esterase activity since the formation rate of R123, which does not require esterases, was also stimulated by MeHg. R123, because of its positive charge, has been used as a measure of mitochondrial membrane potential in

| Incubation mixture | Absorbance at 429 nm* |
|--------------------|------------------------|
| 125 μM deferoxamine + 625 μM FeSO₄ | 0.347 ± 0.005 |
| 125 μM deferoxamine + 625 μM FeSO₄ + 1.25 mM MeHg | 0.357 ± 0.004 |
| 125 μM deferoxamine + 1.25 mM MeHg | <0.001 |
| 125 μM deferoxamine + 625 μM FeSO₄ + 1.25 mM HgCl₂ | 0.345 ± 0.007 |
| 125 μM deferoxamine + 1.25 mM HgCl₂ | <0.001 |

* Each value represents the mean ± SE from three independent measurements.
nerve terminals (Yoshikami and Okun, 1984; Magrassi et al., 1987) and in liver (O’Connor et al., 1988). Preliminary experiments performed in our laboratory indicate that DHR 123 is oxidized to fluorescent R123 in a similar fashion as DCFH (C. P. LeBel and C. S. Bondy, unpublished observations), suggesting that it may also be used as a measure of reactive oxygen species. The localization of R123 in mitochondria (Yoshikami and Okun, 1984; Magrassi et al., 1987), together with findings of the present study and the fact that brain mitochondria are a rich source of reactive oxygen species (Cino and Del Maestro, 1989), supports the theory that mitochondria may be a specific cellular locus for the critical action of MeHg (Cheung and Verity, 1981).

The results obtained with the fluorescent markers used here suggest a role for reactive oxygen species in the mechanism of MeHg neurotoxicity. DCF and R123 formation also appear dependent on the presence of both an iron–peroxide complex (ferryl ion) and other reactive oxygen species (LeBel et al., 1991), which further implicates iron-catalyzed oxygen radical reactions in MeHg toxicity. Furthermore, the use of DCF as a marker for MeHg-induced oxidative cell damage appears to be a more sensitive measure when compared to standard lipoperoxidative techniques. MeHg stimulated the formation of DCF at least two-fold (Figs. 1 and 3), while previous studies in synaptosomes using thiobarbituric acid-reactive products (TBARs) only showed modest increases in TBARs in the presence of 25 µM MeHg (Bondy and McKee, 1990).

Most theories regarding the toxicity of MeHg work on the premise that the intact molecule interacts with protein sulfhydryl groups to produce its toxicity (Ganther, 1978, 1980). An alternative hypothesis is that MeHg undergoes cleavage, leading to the formation of Hg2+ and a methyl radical (Ganther, 1980). It is not likely that the observed increases in DCF formation are due to Hg2+ since its been shown that less than 4% of the mercury burden in the brain existed as inorganic mercury on the tenth day following intravenous injection of MeHg (Norseth and Clarkson, 1970; Racz and Vanderwater, 1982). Regarding the possibility that methyl radical might play a role, its formation is reported to be induced by ascorbate and copper and is thought to be catalyzed by a copper-mediated free radical mechanism (Gage, 1975). The methyl radical, or other radical species, may therefore be linked to the increased oxidation of DCFH following exposure to MeHg.

As mentioned previously, there is an increasing body of information to suggest that one of the mechanisms in the neurotoxicity of MeHg involves iron-catalyzed oxygen radical-induced cell damage. The present study not only supports this theory, but specifically suggests that an iron–peroxide intermediate (ferryl ion) and other reactive oxygen species may play a major role in MeHg-induced cell death. MeHg not only appears to increase the formation of ferryl ion, but several other studies have implicated this reactive oxygen complex as the most probable damage-inducing species (Arai et al., 1987; Yamamoto and Kawanishi, 1989). The postulate has been raised that reactive oxygen species may act as chemical messengers (Saran and Bors, 1989) further supporting the concept that these species may play a critical role in various mechanisms of neurotoxicity (Bondy and LeBel, 1991; LeBel and Bondy, 1991). The fact that parallel in vivo and in vitro effects are observed in studies that show oxygen radical generation enhancement by MeHg and for several other known neurotoxicants (LeBel and Bondy, 1991) demonstrates the usefulness of these fluorescent dyes as sensitive markers for neurotoxicity.

REFERENCES

Abu-Murad, C., and Nordmann, R. (1983). Effect of iron chelators, desferrioxamine and diethylenetriamine pentaacetic acid, on the development of physical dependence on ethanol in mice. Drug Alcohol Depend. 12, 371–379.

Arai, H., Kogure, K., Sugioka, K., and Nakano, M. (1987). Hydroxyl free radical is not the main active species in site-specific DNA damage induced by copper (II), iron, and hydrogen peroxide. Biochem. Int. 14, 741–749.

Aust, S. D., Morehouse, L. A., and Thomas, C. E. (1985). Role of metals in oxygen free radical reactions. J. Free Rad. Biol. Med. 1, 3–25.

Bass, D. A., Parce, J. W., Dechateau, L. R., Szejda, P., Seeds, M. C., and Thomas, M. (1983). Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J. Immunol. 130, 1910–1917.

Bondy, S. C., and LeBel, C. P. (1991). Oxygen radical generation as an index of neurotoxic damage. Biomed. Environ. Sci. 4, 217–223.

Bondy, S. C., and McKee, M. (1990). Prevention of chemically induced synaptosomal changes. J. Neurosci. Res. 25, 229–235.

Cheung, M. K., and Verity, M. A. (1981). Biotransformation of methylmercury inhibition of synaptosomal changes. Arch. Biochem. Biophys. 209, 623–638.

Freeman, B. A., and Crapo, J. D. (1982). Free radicals and tissue aging. Lab. Invest. 47, 412–426.

Gage, J. C. (1975). Desferrioxamine: A scavenger of superoxide radicals. Toxicol. Appl. Pharmacol. 32, 225–238.

Ganter, H. E. (1978). Modification of methylmercury toxicity and metabolism by selenium and vitamin E: Possible mechanism. Environ. Health Perspect. 25, 71–76.

Ganter, H. E. (1980). Interactions of vitamin E and selenium with mercury. Ann. N.Y. Acad. Sci. 355, 212–226.

Hallaway, P. E., Eaton, J. W., Panter, S. S., and Hedlund, B. E. (1989). Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc. Natl. Acad. Sci. USA 86, 10,108–10,112.

Halliwell, B., and Gutteridge, J. M. C. (1984). Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1–14.

Halliwell, B., and Gutteridge, J. M. C. (1985). Oxygen free radicals and the nervous system. Trends Neurosci. 8, 22–26.

Halliwell, B., and Gutteridge, J. M. C. (1986). Oxygen free radicals in relation to biology and medicine. Some problems and concepts. Arch. Biochem. Biophys. 246, 501–514.
SHORT COMMUNICATION

Ikeda, Y., Ikeda, K., and Long, D. M. (1989). Protective effect of the iron chelator desferrioxamine on cold-induced brain edema. J. Neurosurg. 71, 233–238.

Jamieson, D. (1989). Oxygen radicals acting as chemical messengers: A hypothesis. Free Rad. Biol. Med. 7, 87–108.

Kasuya, M. (1975). The effect of vitamin E on the toxicity of alkyl mercurials on nervous tissue in culture. Toxicol. Appl. Pharmacol. 32, 347–354.

Keberle, H. (1964). The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N.Y. Acad. Sci. 119, 758–768.

Kohen, R., and Chevion, M. (1985). Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. Biochem. Pharmacol. 34, 1841–1843.

LeBel, C. P., and Bondy, S. C. (1990). Sensitive and rapid quantitation of reactive oxygen species in rat synaptosomes. Neurochem. Int. 17, 435–440.

LeBel, C. P., and Bondy, S. C. (1991). Oxygen radicals: Common mediators of neurotoxicity. Neurotoxicol. Teratol. 13, 341–346.

LeBel, C. P., Ali, S. F., McKee, M., and Bondy, S. C. (1990). Organometal-induced increases in oxygen reactive species: The potential of 2,7-dichlorofluorescin diacetate as an index of neurotoxic damage. Toxicol. Appl. Pharmacol. 104, 17–34.

LeBel, C. P., Ischiropoulos, H., and Bondy, S. C. (1991). Detection of oxygen reactive species using the probe 2’,7’-dichlorofluorescin, submitted for publication.

Magrassi, L., Purves, D., and Lichtman, J. W. (1987). Use of rhodamine 123 to investigate alterations of mitochondrial activity in isolated mouse liver mitochondria. J. Neurosci. 7, 1207–1214.

Mahoney, J. R., Hallaway, P. E., Hedlund, B. E., and Eaton, J. W. (1989). Acute iron poisoning. J. Clin. Invest. 84, 1362–1366.

Nordmann, R., Ribiere, C., and Rouach, H. (1987). Involvement of iron and iron-catalyzed free radical production in ethanol metabolism and toxicity. Enzyme 37, 57–69.

Norseth, T., and Clarkson, T. W. (1970). Biotransformation of methylmercury salts in the rat studied by specific determination of inorganic mercury. Biochem. Pharmacol. 19, 2775–2783.

O’Connor, J. E., Vargas, J. L., Kimler, B. F., Hernandez-Yago, J., and Grisolia, S. (1988). Generation of hydrogen peroxide by brain mitochondria: The effect of reoxygenation following post-decapitative ischemia. Biochem. Biophys. Res. Commun. 151, 568–573.

Racz, W. J., and Vandewater, L. J. S. (1982). Perspectives on the central nervous system toxicity of methylmercury. Can. J. Physiol. Pharmacol. 60, 1037–1045.

Saran, M., and Bors, W. (1989). Oxygen radicals acting as chemical messengers—A hypothesis. Free Rad. Res. Commun. 7, 213–220.

Smith, C. V. (1987). Evidence for participation of lipid peroxidation and iron in diquat-induced hepatic necrosis in vivo. J. Pharmacol Exp. Therap. 32, 417–422.

Summers, M. R., Jacobs, A., Tudway, D., Perera, P., and Ricketts, C. (1979). Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Haematol. 42, 547–555.

Syverson, T. L. M., Totland, G., and Flood, P. R. (1981). Early morphological changes in rat cerebellum caused by a single dose of methylmercury. Arch. Toxicol. 47, 101–111.

Videla, L. A., Simizu, K., Barros, S. B. M., and Junqueira, V. B. C. (1989). Lindane-induced liver oxidative stress: Respiratory alterations and the effect of desferrioxamine in the isolated perfused rat liver. Cell Biochem. Funct. 7, 179–183.

Westlin, W. F. (1966). Desferrioxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children. Clin. Pediatr. 5, 531–535.

Whitten, C. F., Gibson, G. W., Good, M. H., Goodwin, J. F., and Bough, A. J. (1965). Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: Clinical observations, experimental studies, and theoretical considerations. Pediatrics 36, 322–335.

Whitten, C. F., Chen, Y., and Gibson, G. W. (1966). Studies in acute iron poisoning. II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics 38, 102–110.

Yamamoto, K., and Kawanishi, S. (1989). Oxygen toxicity and reactive oxygen species in mammals. J. Biol. Chem. 264, 15,435–15,440.

Yonaha, M., Saito, M., and Sagai, M. (1983). Stimulation of lipid peroxidation by methyl mercury in rats. Life Sci. 32, 1507–1514.

Yoshikami, D., and Okun, L. M. (1984). Fluorescent probes that stain living nerve terminals. Nature 310, 53–56.

Younes, M., and Siegers, C. P. (1985). The role of iron in the paracetamol- and CCl4-induced lipid peroxidation and hepatotoxicity. Chem. Biol. Interact. 55, 327–334.

CARL P. LeBEL* SYED F. ALI† STEPHEN C. BONDY*

*Department of Community and Environmental Medicine
Southern Occupational Health Center
University of California
Irvine California 92717
†Pharmacodynamics Branch
Division of Reproductive and Developmental Toxicology
National Center for Toxicological Research
Jefferson Arkansas 72079

Received October 3, 1991; accepted October 6, 1991

2 To whom correspondence should be addressed at current address: Alkermes, Inc., 26 Landsdowne Street, Cambridge, MA 02139. Fax: (617) 494-9263.